Salma Health Raises $80M in Series A Funding for Integrated Brain Health Platform
Salma Health just stepped out of stealth with $80M in Series A funding and a mission that cuts straight to one of the most fragmented corners of medicine: brain health. The round was co led by Mubadala Capital and ARCH Venture Partners with participation from Lingotto Horizon and Averin Capital. Serious capital for a problem that has been quietly waiting for someone to treat the brain like a system instead of a scattered set of symptoms.
Credit where it is due. Congratulations to Alaa Halawa, Co founder and CEO of Salma Health, and Brandon Bentzley, MD, PhD, Co founder and CMO. Respect also to the founding team members Ayman AlAbdallah, Emily Phillips Bru, and Zeena Ojjeh. 5 people staring at the same messy problem and deciding to build something cohesive is how new categories tend to start.
And make no mistake, brain health is messy. Psychiatry over here. Neurology down the hall. Therapy in another building. Diagnostics somewhere else entirely. Patients bounce around like a pinball while everyone treats a piece of the puzzle. Salma Health looked at that maze and decided the brain deserved a single front door.
The company is building integrated brain health centers of excellence that combine psychiatry, neurology, psychotherapy, and interventional treatments inside one coordinated care model. Clinics are already operating in Orange County, San Diego, and the Bay Area, with Los Angeles next on the horizon. Physical clinics on the ground paired with Brain Health OS, an AI powered operating system designed to personalize treatment, track outcomes, and help clinicians match the right intervention to the right patient at the right moment.
The clinical backbone matters too. Brandon Bentzley helped develop the FDA cleared SAINT neuromodulation protocol, one of the fastest acting approaches for treatment resistant depression. Pair that kind of clinical firepower with advanced diagnostics, generative AI, and coordinated care pathways and suddenly the phrase brain health starts to sound less like philosophy and more like engineering.
Investors noticed. Mubadala Capital and ARCH Venture Partners do not throw $80M at a concept unless the architecture underneath it is real. Lingotto Horizon and Averin Capital joining the round signals the same thing. The bet here is not just clinics. It is data, outcomes, and a smarter operating system for one of the most complex organs in the human body.
The real lesson for founders is hiding in plain sight. Big funding rounds rarely start with money. They start with clarity. Salma Health focused on a painfully obvious gap, spent years building the infrastructure, and only then stepped into the light with a model that connects diagnostics, technology, and treatment into one rhythm.